After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Aclaris Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Diagnostics & Research industry. The current market capitalization of Aclaris Therapeutics Inc is $85.81M. A total of 1.07 million shares were traded on the day, compared to an average of 1.30M shares.
In the most recent transaction, Powell Andrew Kenneth William bought 6,000 shares of ACRS for 1.25 per share on Mar 04 ’24. After the transaction, the Director now owns 28,863 company shares. In a previous transaction on Mar 01 ’24, Powell Andrew Kenneth William bought 8,500 shares at 1.23 per share. ACRS shares that Director owns now total 22,863.
Among the insiders who sold shares, Monahan Joseph disposed of 6,000 shares on Oct 23 ’23 at a per-share price of $5.08. This resulted in the Chief Scientific Officer holding 129,724 shares of ACRS after the transaction. In another insider transaction, Balthaser Kevin bought 9,490 shares at $7.90 per share on Sep 06 ’23. Company shares held by the Chief Financial Officer now total 15,461.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ACRS has a high of $11.12 and a low of $0.59.
As of this writing, ACRS has an earnings estimate of $Aclaris Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Axcelis Technologies, Inc. estimates, with a high estimate of $Ares Commercial Real Estate Cor per share and a lower estimate of $Carpenter Technology Corporatio.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ACRS’s latest balance sheet shows that the firm has $191.41M in Cash & Short Term Investments as of fiscal 2021. There were $693.00k in debt and $22.93M in liabilities at the time. Its Book Value Per Share was $2.22, while its Total Shareholder’s Equity was $197.34M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACRS is Buy with a score of 3.22.
